Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study.

Lea HoisnardAntoine MeyerRosemary Dray-SpiraAlain WeillMahmoud ZureikEmilie Sbidian

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

In this nationwide cohort study, the rates of GIPs did not differ between groups of patients who received JAKi and adalimumab treatment. These results need to be confirmed in other observational studies.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
ulcerative colitis
hidradenitis suppurativa
cross sectional
disease activity